According to business standards, the Indian pharmaceutical industry is a global powerhouse, projected to reach $130 billion by 2030, growing at over 10% annually. Currently valued at $50 billion, India supplies 20% of the world’s generic medicines and accounts for 60% of global vaccine production, cementing its role as the “pharmacy of the world.
With a market capitalization of Rs 18,205.80 crore, the shares of Neuland Laboratories Ltd closed at Rs 14,110.05 per share, increased around 12.87 percent as compared to the previous closing price of Rs 12,500.75 apiece.
Stock Performance:-
In the previous six months, the stock has delivered multi-bagger returns of nearly 112.72 percent, while around 271.27 percent in a year. So far in 2024, it has given about 271.27 percent of multi-bagger returns.
The stock has delivered multi-bagger returns of around 3,193 percent over five years, spanning from Rs. 430 in Jan 2020 to the current stock price level of Rs. 14,136.85 apiece.
This indicates that if an investor had invested Rs. 10,000 in the stock four years ago, it would have gained to nearly Rs.3.29 lakhs.
Financial performance:-
The company’s total income for Q1 FY25 was ₹444.4 crores, marking a 21.7% growth from ₹365 crores in Q1 FY24. EBITDA (excluding exceptional items) reached ₹128.6 crores with a margin of 28.9%, a 174 bps YoY improvement. Gross margins rose to 66.1%.
Profit after tax for Q1 FY25 increased to ₹98.3 crores, up from ₹62.2 crores in Q1 FY24, benefiting from a ₹20.6 crores exceptional gain from the sale of surplus investment property. The company generated ₹50.9 crores in free cash flow, with a net debt position of negative ₹110.2 crores.
Business Transition:-
The company is transitioning from a focus on prime APIs to a balanced portfolio of CMS (Contract Manufacturing Services) and GDS (Generic Drug Substances). CMS revenues reached ₹235 crores, driven by commercial molecules, with strong performance in specialty APIs like Dorzolamide and Donepezil, alongside key products like Mirtazapine and Escitalopram.
Market outlook:-
The company views FY25 as a year of consolidation with normalized revenues and profits, reflecting its investment phase. Growth momentum is expected to pick up from FY26, driven by new manufacturing facilities and commercial launches. Management remains cautiously optimistic despite inherent business variability.
Capacity Expansion:-
The company expects new production blocks in Unit-3 to be operational by H2 FY26. Currently, capacity utilization in Units 1 and 2 exceeds 90%, and ongoing expansion in Unit 1 is underway to meet growing demand, supporting the company’s future growth and production needs.
Challenges & Customer Engagement:-
Management recognizes risks such as currency fluctuations, raw material cost volatility, and geopolitical instability, and is actively mitigating supply chain risks by seeking alternatives to China.
Increased customer interest, particularly from biotech firms, has expanded the project pipeline, while ongoing engagement has strengthened relationships through additional molecule projects.
Company summary:-
Neuland Laboratories Limited is engaged in the manufacturing and selling of bulk drugs. The Company caters to both domestic and international markets. It manufactures active pharmaceutical ingredients (APIs) and is an end-to-end solution provider for the pharmaceutical industry’s chemistry needs.
Written by:- Abhishek Singh
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
